Importance It has become common practice to offer immunocompromised patients with
hematologic cancers a third COVID-19 vaccination dose, but data substantiating this are scarce. …

Patients with hematologic conditions have a higher risk of severe COVID-19 and COVID-19-related
death. This is related to immune deficiencies induced by hematologic conditions and/…

Vaccination guidelines for patients treated for hematological diseases are typically conservative.
Given their high risk for severe COVID-19, it is important to identify those patients that …

Background The aim of this randomized, controlled trial is to determine whether antisevere
acute respiratory syndrome coronavirus 2 hyperimmune globulin (COVIG) protects against …

Background Patients with haematological malignancies have impaired antibody responses
to SARS-CoV-2 vaccination. We aimed to investigate whether a fourth mRNA COVID-19 …

Background Liver regeneration following partial hepatectomy (PHx) is a complicated
process involving multiple organs and several types of signaling networks. The bile acid-activated …

Background: Sorafenib for advanced hepatocellular carcinoma (HCC) is dose adjusted by
toxicity. Preliminary studies have suggested an association between plasma concentrations of …

Importance In patients with hematologic malignancies, the immunogenicity of the standard 2-dose
mRNA-1273 coronavirus disease 19 (COVID-19) vaccination schedule is often …

Introduction COVID-19 vaccination protects against a severe course of COVID-19. Nevertheless,
individuals with hematologic malignancies (HM) remain at increased risk of COVID-19-…

Background: Prior to the introduction of COVID-19 vaccines, SARS-CoV-2 infection in individuals
with haematologic malignancies was associated with a high risk for severe COVID-19. …